A PHASE IIB RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTRE, DOSE-RANGING STUDY OF AZD3427 IN PARTICIPANTS WITH HEART FAILURE AND PULMONARY HYPERTENSION DUE TO LEFT HEART DISEASE (WHO GROUP 2)
- Registry ID
- D8330C00003
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE2
- Study type
- INTERVENTIONAL
- Sponsor
- ASTRAZENECA AB
- Start date
- 2023-10-26
- Last update
- 2023-03-30
Conditions
- PULMONARY HYPERTENSION
- HEART FAILURE
- HEART DISEASE
Related clinical trials
- EFFICACY AND SAFETY OF NNC0487-0111 COMPARED TO PLACEBO ON MORBIDITY AND MORTALITY IN PEOPLE WITH HEART FAILURE WITH PRESERVED OR MILDLY REDUCED EJECTION FRACTION AND OBESITY (HF-POLARIS)
- A MULTI-CENTER, RANDOMIZED, PARTICIPANT- AND INVESTIGATOR- BLINDED, PLACEBO-CONTROLLED CROSSOVER STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF HJB647 IN PARTICIPANTS WITH CHRONIC STABLE HEART FAILURE WITH REDUCED OR MILDLY REDUCED EJECTION FRACTION (HFREF/HFMREF)
- ORAL L-CARNITINE SUPPLEMENTATION IN CARDIORENAL HEART FAILURE PATIENTS
- A PHASE 2A, OPEN-LABEL, SINGLE ARM MULTICENTER EXPLORATORY STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND EFFICACY OF ORAL DOSES OF ROC-101 IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION (PAH) AND PULMONARY HYPERTENSION ASSOCIATED WITH INTERSTITIAL LUNG DISEASE (ILD-PH)
- A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO INVESTIGATE THE EFFICACY, SAFETY, AND PK/ PD OF FINERENONE, IN ADDITION TO STANDARD-OF-CARE, IN PEDIATRIC PATIENTS, 6 MONTHS TO < 18 YEARS OF AGE WITH HEART FAILURE (HF) AND LEFT VENTRICULAR SYSTOLIC DYSFUNCTION (LVSD)
- A PHASE 3, SINGLE-ARM, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE SAFETY OF FINERENONE IN ADDITION TO STANDARD OF CARE, IN PEDIATRIC HEART FAILURE PATIENTS, FROM BIRTH TO 18 YEARS OF AGE, WITH LEFT VENTRICULAR SYSTOLIC DYSFUNCTION (LVSD)
View on source registry